Int J Cancer: Scientists are expected to use a multigene risk scoring system to predict the risk of common cancers in the population.

August 19, 2020 // -- Scientists from Vanderburg University and other institutions have made significant progress in cancer prevention research in a recent study published in the international journal International Journal of Cancer entitled "Evaluating polygenic risk scores in assessing risk of nine solids and hematologic cancers in Europeans".
Photo Source: Pixabay/CC0 Public Domain The incidence and mortality rate of cancer around the world has increased rapidly in recent years, and despite the complexity behind this, scientists are still struggling to find high-risk groups that are vulnerable to cancer screening.
'In this study, we used a multigene risk score (PRS) to predict the risk of common cancers in the population, including prostate, breast and colon cancer, and the multigene risk score summarized the combined effects of multiple gene mutations,' said Wei Zheng, M.D.
now, researchers are using new technology to evaluate nine less common cancers, including melanoma, glioma and chronic lymphocytic leukemia, which account for about 24 percent of cancer deaths worldwide. In the
paper, researchers studied 400,807 people of European descent from the UK's biosatric pool, conducted genome-wide correlation studies of data collected from these populations, and found that 63 percent of participants more than tripled their risk of developing at least one cancer through a multigene risk scoring system.
Finally, the researchers said the study sheds light on the importance of multigene risk scoring systems in identifying people at high risk of cancer, and they will continue to study in depth the use of such scoring systems to effectively assess cancer risk in different populations, thereby effectively preventing cancer in populations.
original source: Jungyoon Choi, Guochong Jia, Wanqing Wen, et al. Evaluating polygenic risk scores in assessing risk of nine solid and hematologic cancers in Europeans, International Journal of Cancer (2020). DOI: 10.1002/ijc.33176.